-
DSMB Decision on Celldex's (CLDX) RINTEGA was No Surprise; 'Focus Pick' Rating Reaffirmed
-
Roth Affirms Celldex (CLDX) at 'Focus Pick'; Solidifying Itself as Premier Cancer Immunotherapy Company
-
Celldex Announces Exercise of Underwriters' Option to Purchase Additional Shares
-
Celldex Therapeutics Prices Public Offering of Common Stock
-
Breakthrough Designation for Celldex's (CLDX) Rintega Points to Stronger FDA Support as Cancer Vaccine in GBM - Roth Capital
-
Roth Capital Still Positive on Celldex (CLDX) Upon Completion of Phase III ACT IV Enrollment
-
Roth Comments on Celldex (CLDX) Following Initiation of CDX-011 Phase II
-
Pre-Open Stock Movers 11/17: (CLDX) (BHI) (AGN) Higher; (DWA) (GSAT) (HAL) Lower (more...)
-
Roth Capital Lifts PT on Celldex (CLDX) to $43 Following Phase 2 ReACT Presentation
-
Streetinsider.com's Hot Lunchtime Reads 11/10: (TWTR) (HIMX) (SVU) (AGU)
-
Roth Capital 'Encouraged' by PoC Data from Celldex's (CLDX) Varlilumab Phase 1
-
Roth Keeps Celldex (CLDX) at 'Focus Pick'; Strong Phase I Data for Varlilumab Only Adds to Story
-
Another Partnership in the Books, Focus Now on ASCO for Celldex (CLDX) - Roth
-
Celldex (CLDX) Upcoming Clinical Data, Study Expansions, Pipeline Keep Roth Positive; 'Focus List' Rating Affirmed
-
Roth Capital Upgrades Celldex Therapeutics (CLDX) to Buy
-
Roth Capital Initiates Coverage Biotechnology and Drugs KERX & CLDX